Results 61 to 70 of about 11,256 (207)
, 2020 Image Crops for Hewitt et al 2020 "Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with ...
Hewitt, G (via Mendeley Data) +1 more
core +2 more sources
Advanced Science, EarlyView.This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng +7 more
wiley +1 more source
Advanced Science, EarlyView.A lactate‐H3K18la epigenetic axis upregulates RPL11 to drive gemcitabine resistance in pancreatic cancer. RPL11 orchestrates chemoresistance through a dual, compartmentalized role: enhancing cytoplasmic protein synthesis via EEF1A1 stabilization and promoting nuclear DNA damage repair by co‐activating PARP14, thus ensuring robust cell survival ...
Lijun Zhao +10 more
wiley +1 more source
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
Frontiers in Oncology, 2020 Poly (ADP-ribose) polymerase (PARP) inhibitors are a therapeutic milestone exerting a synthetic lethal effect in the treatment of cancer involving BRCA1/2 mutation.
Ye Han +4 more
doaj +1 more source
Advanced Science, EarlyView.BRCA1 mutation‐responsive FBOA‐tFNA selectively recognizes mutant transcripts and coordinates reduction‐responsive intracellular delivery of olaparib and adavosertib, amplifying DNA damage and weakening G2/M checkpoint protection. These effects are accompanied by STING‐associated immune activation and stronger antitumor immunity, while sequential anti ...
Chenyi Wang +7 more
wiley +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia +35 more
wiley +1 more source
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer +20 more
wiley +1 more source
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
Cell Reports, 2020 Summary: PARP inhibitors (PARPi) cause synthetic lethality in BRCA-deficient tumors. Whether specific vulnerabilities to PARPi exist beyond BRCA mutations and related defects in homology-directed repair (HDR) is not well understood. Here, we identify the
Marco Gatti +4 more
doaj +1 more source
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Therapeutic Advances in Medical Oncology, 2023 Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of ‘synthetic lethality’ is exploited by PARPi in tumors with defects in DNA repair pathways, particularly ...
Ana C. Veneziani +4 more
doaj +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source